BW-15

BW-15 is an investigational small interfering RNA (siRNA) therapeutic being developed by Shanghai Argo Biopharmaceutical for the treatment of cardiovascular disease. Developed using Argo's proprietary RNAi Activating Delivery System (RADS), BW-15 is designed to silence a specific mRNA target in the liver to reduce the expression of a protein involved in cardiovascular pathology. By utilizing RNA interference (RNAi), the drug aims to achieve potent and durable knockdown of its target, potentially offering a long-acting treatment option with infrequent dosing. While the specific molecular target of BW-15 has not been publicly disclosed by the company, it is part of a robust cardiovascular pipeline that includes programs targeting proteins such as ANGPTL3, Lp(a), and Factor XI. As of early 2024, BW-15 is in the preclinical stage of development.